In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire Azstarys from Corium Therapeutics, the FDA grants accelerated approval to Wegovy HD, a higher-dose version of Novo Nordisk's semaglutide injection, supported by Phase III data showing roughly 21% mean weight loss, and an analysis on agentic AI and what it means for commercial operations in life sciences.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire Azstarys from Corium Therapeutics, the FDA grants accelerated approval to Wegovy HD, a higher-dose version of Novo Nordisk's semaglutide injection, supported by Phase III data showing roughly 21% mean weight loss, and an analysis on agentic AI and what it means for commercial operations in life sciences.
In deal news, Novartis has agreed to acquire SNV4818, a pan-mutant-selective inhibitor in Phase I/II development for hormone receptor-positive, HER2-negative breast cancer, through the purchase of Synnovation's wholly owned subsidiary Pikavation Therapeutics for $2 billion upfront and up to $1 billion in milestones. Separately, Collegium Pharmaceutical has agreed to acquire Azstarys, a combined immediate- and extended-release ADHD therapy that logged more than 760,000 prescriptions in 2025, from Corium Therapeutics.
The FDA has granted accelerated approval to Wegovy HD, a once-weekly injectable semaglutide at 7.2 mg , three times the previously approved maximum dose, for long-term weight reduction in adults with obesity. The decision was supported by the STEP UP Phase III trial, in which participants achieved a mean weight loss of 20.7 percent, with roughly one in three reaching 25 percent or greater weight loss. The FDA awarded a Commissioner's National Priority Voucher for the approval, and Novo Nordisk expects to launch the product in a single-dose pen at U.S. pharmacies in April 2026.
Finally, An analysis on agentic AI and the future of commercial excellence in life sciences, a topic that continues to generate significant industry discussion. The piece argues that fragmented data environments and siloed workflows are limiting companies' ability to act on commercial insights at competitive speed, and that agentic systems capable of orchestrating territory management, field guidance, and campaign personalization represent a meaningful operational shift. The authors contend that success will belong to organizations that invest in data governance and change management before deploying these tools broadly.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
